Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices
暂无分享,去创建一个
Paul J Catalano | Danielle S Bitterman | Daniel N Cagney | Lisa Singer | Paul L Nguyen | Raymond H Mak | P. Catalano | R. Mak | D. Bitterman | D. Cagney | L. Singer | P. Nguyen
[1] B. Kavanagh. Radiation Oncology APM: Why Us? Why Now? , 2019, International journal of radiation oncology, biology, physics.
[2] Lorenzo Trippa,et al. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data , 2019, Clinical Cancer Research.
[3] Peter G Maxim,et al. PHASER: A platform for clinical translation of FLASH cancer radiotherapy. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] Michael G. Endres,et al. Use of Crowd Innovation to Develop an Artificial Intelligence–Based Solution for Radiation Therapy Targeting , 2019, JAMA oncology.
[5] G. Rosner,et al. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology , 2018, Journal of the National Cancer Institute.
[6] V. Gebski,et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer , 2018, The New England journal of medicine.
[7] Suresh Senan,et al. Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases. , 2018, International journal of radiation oncology, biology, physics.
[8] Jacqueline Corrigan-Curay,et al. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. , 2018, JAMA.
[9] Hiroyuki Sato,et al. Master protocol trials in oncology: Review and new trial designs , 2018, Contemporary clinical trials communications.
[10] Ying Sun,et al. Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years , 2018, JAMA oncology.
[11] Nhat-Long Pham,et al. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma. , 2018, International journal of radiation oncology, biology, physics.
[12] J. Bourhis,et al. The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients , 2018, Clinical Cancer Research.
[13] Sean Khozin,et al. Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study. , 2018, Health affairs.
[14] N. Hardcastle,et al. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel), a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. , 2018, The British journal of radiology.
[15] Radhe Mohan,et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Nahon,et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. , 2017, Journal of hepatology.
[17] S. Khozin,et al. Real-world Data for Clinical Evidence Generation in Oncology. , 2017, Journal of the National Cancer Institute.
[18] M. V. van Herk,et al. The Future of Image-guided Radiotherapy. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).
[19] Thomas Bortfeld,et al. Three ways to make proton therapy affordable , 2017, Nature.
[20] J. Woodcock,et al. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.
[21] T. Pawlicki,et al. Medical Device Recalls in Radiation Oncology: Analysis of US Food and Drug Administration Data, 2002-2015. , 2017, International journal of radiation oncology, biology, physics.
[22] J. Bourhis,et al. Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: Results of the GORTEC 2004-01 randomized trial. , 2017 .
[23] Mithat Gönen,et al. An efficient basket trial design , 2017, Statistics in medicine.
[24] Gail Pearson,et al. Efficient design of clinical trials and epidemiological research: is it possible? , 2017, Nature Reviews Cardiology.
[25] C. Fuller,et al. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology , 2017, Front. Oncol..
[26] Zhifei Wen,et al. The future of image-guided radiotherapy will be MR guided. , 2017, The British journal of radiology.
[27] Marco Durante,et al. Charged-particle therapy in cancer: clinical uses and future perspectives , 2017, Nature Reviews Clinical Oncology.
[28] Reshma Jagsi,et al. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. , 2017, International journal of radiation oncology, biology, physics.
[29] C. Begg,et al. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Sargent,et al. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] T. Pawlicki,et al. Adverse Events Involving Radiation Oncology Medical Devices: Comprehensive Analysis of US Food and Drug Administration Data, 1991 to 2015. , 2017, International journal of radiation oncology, biology, physics.
[32] Tianyu Zhao,et al. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. , 2016, International journal of radiation oncology, biology, physics.
[33] S. Mutic,et al. Magnetic Resonance Image Guided Radiation Therapy for External Beam Accelerated Partial-Breast Irradiation: Evaluation of Delivered Dose and Intrafractional Cavity Motion. , 2016, International journal of radiation oncology, biology, physics.
[34] D. Elashoff,et al. IMRT for head and neck cancer: Cost implications. , 2016, American journal of otolaryngology.
[35] Li Shen,et al. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Michael Hogarth,et al. Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.
[37] M. Mehta,et al. A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy , 2016, Cancer.
[38] J. Efstathiou,et al. Beyond a moonshot: insurance coverage for proton therapy. , 2016, The Lancet. Oncology.
[39] S. Kannan,et al. Prospective randomized controlled trial to compare 3‐dimensional conformal radiotherapy to intensity‐modulated radiotherapy in head and neck squamous cell carcinoma: Long‐term results , 2016, Head & neck.
[40] Indrin J Chetty,et al. Technology for Innovation in Radiation Oncology. , 2015, International journal of radiation oncology, biology, physics.
[41] Mary W Redman,et al. The Master Protocol Concept. , 2015, Seminars in oncology.
[42] Mary W Redman,et al. Lung-MAP--framework, overview, and design principles. , 2015, Chinese clinical oncology.
[43] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[44] J. Pignol,et al. The evaluation of innovation in radiation oncology – what can we do and what should we do? , 2015, Acta oncologica.
[45] F. Hirsch,et al. Innovative Clinical Trials: The LUNG‐MAP Study , 2015, Clinical pharmacology and therapeutics.
[46] R. Pötter,et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. , 2015, The Lancet. Oncology.
[47] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[48] Daniel V.T. Catenacci,et al. Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity , 2014, Molecular oncology.
[49] S. Hahn,et al. Reference pricing with evidence development: a way forward for proton therapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Salim Yusuf,et al. When it comes to trials, do we get what we pay for? , 2013, The New England journal of medicine.
[51] Johannes A Langendijk,et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[52] Jan Bogaerts,et al. Designing transformative clinical trials in the cancer genome era. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Kannan,et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[54] S. Zhang,et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[55] H. Glick,et al. Costing and Cost Analysis in Randomized Controlled Trials , 2012, PharmacoEconomics.
[56] J. Moran,et al. Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. , 2012, Seminars in radiation oncology.
[57] D. Challoner,et al. Medical Devices and the Public's Health: The FDA 510(k) Clearance Process at 35 Years , 2011 .
[58] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[59] Samuel R Mazin,et al. Emission-guided radiation therapy: biologic targeting and adaptive treatment. , 2010, Journal of the American College of Radiology : JACR.
[60] Brian O'Sullivan,et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] D. Solís. US Food and Drug Administration , 2010 .
[62] Jane M Blazeby,et al. Challenges in evaluating surgical innovation , 2009, The Lancet.
[63] L. Feldman,et al. Evaluation and stages of surgical innovations , 2009, The Lancet.
[64] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[65] S. Bentzen,et al. Balancing on a knife's edge: evidence-based medicine and the marketing of health technology. , 2008, International journal of radiation oncology, biology, physics.
[66] Indira Madani,et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. , 2008, The Lancet. Oncology.
[67] Salim Yusuf,et al. Specific barriers to the conduct of randomized trials , 2008, Clinical trials.
[68] J C Dumville,et al. The use of unequal randomisation ratios in clinical trials: a review. , 2006, Contemporary clinical trials.
[69] D. Berry. Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.
[70] R. Jagsi,et al. Real-time rationing of scarce resources: the Northeast Proton Therapy Center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] I. B. Borel Rinkes,et al. Initial experience with radiofrequency ablation for hepatic tumours in the Netherlands. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[72] J M Lachin,et al. Statistical properties of randomization in clinical trials. , 1988, Controlled clinical trials.
[73] B. Freedman. Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.